GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BG Medicine Inc (OTCPK:BGMD) » Definitions » Piotroski F-Score
中文

BG Medicine (BG Medicine) Piotroski F-Score

: 0 (As of Today)
View and export this data going back to 2011. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BG Medicine has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for BG Medicine's Piotroski F-Score or its related term are showing as below:


BG Medicine Piotroski F-Score Historical Data

The historical data trend for BG Medicine's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BG Medicine Annual Data
Trend Dec05 Dec06 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 3.00 3.00 5.00

BG Medicine Quarterly Data
Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 2.00 3.00 5.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec15) TTM:Last Year (Dec14) TTM:
Net Income was -1.348 + -2.029 + -1.023 + -0.902 = $-5.30 Mil.
Cash Flow from Operations was -1.391 + -0.827 + -0.332 + -1.117 = $-3.67 Mil.
Revenue was 0.437 + 0.505 + 0.334 + 0.29 = $1.57 Mil.
Gross Profit was 0.288 + 0.333 + 0.231 + 0.208 = $1.06 Mil.
Average Total Assets from the begining of this year (Dec14)
to the end of this year (Dec15) was
(5.229 + 2.59 + 1.366 + 3.356 + 2.133) / 5 = $2.9348 Mil.
Total Assets at the begining of this year (Dec14) was $5.23 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $1.95 Mil.
Total Current Liabilities was $1.18 Mil.
Net Income was -2.179 + -2.169 + -2.397 + -1.32 = $-8.07 Mil.

Revenue was 0.739 + 0.799 + 0.695 + 0.554 = $2.79 Mil.
Gross Profit was 0.491 + 0.518 + 0.461 + 0.362 = $1.83 Mil.
Average Total Assets from the begining of last year (Dec13)
to the end of last year (Dec14) was
(9.353 + 6.172 + 11.24 + 7.571 + 5.229) / 5 = $7.913 Mil.
Total Assets at the begining of last year (Dec13) was $9.35 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $4.85 Mil.
Total Current Liabilities was $4.58 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BG Medicine's current Net Income (TTM) was -5.30. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BG Medicine's current Cash Flow from Operations (TTM) was -3.67. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec14)
=-5.302/5.229
=-1.0139606

ROA (Last Year)=Net Income/Total Assets (Dec13)
=-8.065/9.353
=-0.86229017

BG Medicine's return on assets of this year was -1.0139606. BG Medicine's return on assets of last year was -0.86229017. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

BG Medicine's current Net Income (TTM) was -5.30. BG Medicine's current Cash Flow from Operations (TTM) was -3.67. ==> -3.67 > -5.30 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec14 to Dec15
=0/2.9348
=0

Gearing (Last Year: Dec14)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec13 to Dec14
=0/7.913
=0

BG Medicine's gearing of this year was 0. BG Medicine's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec15)=Total Current Assets/Total Current Liabilities
=1.951/1.18
=1.65338983

Current Ratio (Last Year: Dec14)=Total Current Assets/Total Current Liabilities
=4.851/4.579
=1.05940162

BG Medicine's current ratio of this year was 1.65338983. BG Medicine's current ratio of last year was 1.05940162. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

BG Medicine's number of shares in issue this year was 11.264. BG Medicine's number of shares in issue last year was 8.618. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.06/1.566
=0.67688378

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.832/2.787
=0.65733764

BG Medicine's gross margin of this year was 0.67688378. BG Medicine's gross margin of last year was 0.65733764. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec14)
=1.566/5.229
=0.29948365

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec13)
=2.787/9.353
=0.29797926

BG Medicine's asset turnover of this year was 0.29948365. BG Medicine's asset turnover of last year was 0.29797926. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BG Medicine has an F-score of 5 indicating the company's financial situation is typical for a stable company.

BG Medicine  (OTCPK:BGMD) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


BG Medicine Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of BG Medicine's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BG Medicine (BG Medicine) Business Description

Traded in Other Exchanges
N/A
Address
303 Wyman Street, Suite 300, Waltham, MA, USA, 02451
BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Executives
Jeffrey R Luber director 100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stelios Papadopoulos director 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Harry W Wilcox director ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139
Agtc Partners, L.p. 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Newcogen Group, Inc. 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Applied Genomic Technology Capital Fund Lp 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Flagship Pioneering Inc. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Agtc Advisors Fund Lp 10 percent owner ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142
Kania Edwin M Jr 10 percent owner
Flagship Ventures Fund 2007, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures 2007 General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Stephane Bancel director 320 BENT STREET, CAMBRIDGE MA 02141
Harris Timothy J.r. director C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451

BG Medicine (BG Medicine) Headlines

No Headlines